Double Filtration Plasmapheresis (DFPP) for Spike Protein Removal: What the Evidence Shows

Double filtration plasmapheresis (DFPP) represents one of the most discussed clinical interventions for removing persistent spike protein from circulation. Unlike standard therapeutic plasma exchange, DFPP uses a two-stage filtration system that selectively removes large molecular weight substances—including immunoglobulins, immune complexes, and viral particles—while returning albumin and smaller proteins to the patient.

How DFPP Works: The Two-Filter Cascade

Standard plasmapheresis separates plasma from blood cells, then discards the plasma entirely (replacing it with albumin or fresh frozen plasma). DFPP improves on this by adding a second fractionation filter. The first filter separates plasma from cellular components. The second filter selectively retains high-molecular-weight molecules (>60 nm diameter), including IgM, IgG, immune complexes, lipoproteins, and—critically—viral particles like SARS-CoV-2 (60–140 nm diameter).

This selective approach offers two advantages: patients retain more of their own plasma proteins (particularly albumin), and the process specifically targets the size range where spike protein, spike-laden extracellular vesicles, and circulating immune complexes reside.

Key Technical Parameters:

• First filter: Plasma separator (0.2–0.5 μm pore size) separates plasma from blood cells
• Second filter: Fractionation filter (e.g., Evaflux 2A20) with ~30 nm cutoff retains large molecules
• Session volume: Typically 1–1.5 plasma volumes per session (2.5–4 liters)
• Protocol: 4–8 sessions over 2–3 weeks, sometimes with maintenance sessions

The Clinical Evidence: What Do We Actually Know?

Early Promise: Case Reports and Observational Data (2020–2023)

DFPP was originally developed for conditions like familial hypercholesterolemia and antibody-mediated kidney disease. Its application to COVID-19 began during the acute pandemic, where case reports documented improvements in critically ill patients. A landmark observational study from Dr. Beate Jaeger's clinic in Germany (2023) treated 17 severe long COVID patients with H.E.L.P. apheresis (a DFPP variant). The results were striking:

• 16 of 17 patients reported significant immediate improvement
• 12 of 17 patients reached near-full recovery
• Fibrinogen levels dropped >30% after a single session
• 15 of 17 maintained improvements at 6–10 month follow-up

These findings drove a surge of medical tourism, with patients spending $20,000–$50,000 at private European clinics.

The Definitive Trial: Nature Communications (February 2025)

The most rigorous evidence came from España-Cueto et al., published in Nature Communications (2025)—a phase II, double-blind, placebo-controlled, randomized trial. Fifty patients with moderate-to-severe long COVID received either six sessions of actual therapeutic plasma exchange (TPE) or a sophisticated sham procedure (blood circulated through sterile saline without plasma removal). Both patients and physicians were fully blinded.

The result: no significant difference between active treatment and placebo across any measured outcome.

Source: España-Cueto et al., Nature Communications, 2025. NCT05445674

Important caveat: This trial used standard TPE, not DFPP specifically. The average time from infection to treatment was two years—far longer than the 2–7 months in the positive case reports. Researchers acknowledged that earlier intervention might yield different results, and that more targeted approaches (immunoadsorption, DFPP) warrant separate investigation.

DFPP-Specific Evidence: Immunoadsorption and Targeted Approaches

A Lancet Infectious Diseases systematic review confirmed a strong association between long COVID and GPCR-targeting autoantibodies. Four small studies (175 total participants) using immunoadsorption to selectively remove these autoantibodies showed:

• Measurable decreases in autoantibody titers
• Clinical improvement in the largest study (123 participants)
• Results still limited by small size and lack of control groups

INUSpheresis, a DFPP variant, has shown modulation of short-term immune-inflammatory indices and effective removal of heavy metals, volatile organic compounds, and organic pollutants, with demonstrated selective removal of high-molecular-weight proteins while sparing albumin.

Who Is Exploring DFPP for Spike Protein Removal?

Several clinics worldwide offer DFPP or related apheresis for long COVID, though primarily outside mainstream hospital systems:

• Dr. Beate Jaeger's clinic (Germany): Pioneered H.E.L.P. apheresis for long COVID
• INUSpheresis centers (Germany, Cyprus): Modified DFPP targeting microclots and autoantibodies
• Integrative medicine clinics (US, UAE): Offering various apheresis protocols

Risks and Considerations

• Cost: $3,000–$10,000 per session, typically not covered by insurance
• Side effects: Blood pressure drops, citrate-induced hypocalcemia, bleeding risk, infection at catheter site
• Rebound effect: Autoantibodies and inflammatory proteins redistribute from tissues within 1–2 days, requiring multiple closely spaced sessions
• Evidence level: No large-scale RCT has validated DFPP specifically for long COVID/spike removal

The Bottom Line

DFPP represents a mechanistically plausible approach to removing circulating spike protein and associated inflammatory mediators. However, the 2025 RCT failed to show benefit for standard plasma exchange in established long COVID. The key open question is whether more targeted filtration (DFPP, immunoadsorption) initiated earlier in the disease course could yield better results. Until properly controlled trials of DFPP specifically are completed, this remains an experimental intervention with promising theoretical basis but insufficient clinical proof.

For patients considering DFPP, the decision should be made in consultation with a physician experienced in apheresis, with realistic expectations about the current evidence base and significant financial cost.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before pursuing any treatment.

References

1. España-Cueto S, et al. Plasma exchange therapy for the post COVID-19 condition. Nature Communications. 2025;16:1831.
2. Jaeger B, et al. H.E.L.P. apheresis for long COVID: observational outcomes. Infect Dis: Diagn Treat. 2023.
3. Antar AAR, et al. Long COVID and viral persistence. Lancet Infect Dis. 2024.
4. Rong Z, et al. SARS-CoV-2 spike protein accumulation in skull-meninges-brain axis. Cell Host Microbe. 2024;32:1854–1869.
5. Swank Z, et al. Persistent circulating SARS-CoV-2 spike antigen in long COVID. Clin Infect Dis. 2023;76(3):e487–e490.
6. Clinical improvement of Long-COVID associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol Psychiatry. 2023.

Related Reading:

• Spike Protein Detox: Separating Evidence from Hype
• Nattokinase and Spike Protein: What the Science Says
• The Complete Spike Protein Detox Protocol: Evidence Review